Literature DB >> 20419463

Cerebral tuberculoma in a patient receiving anti-TNF alpha (adalimumab) treatment.

Karen Lynch1, Michael Farrell.   

Abstract

We report a case of a cerebral tuberculoma in a 60-year-old woman with rheumatoid arthritis while receiving the anti-tumor necrosis factor alpha monoclonal antibody, adalimumab (Humira), for active disease. MR brain imaging for dyspraxia revealed a left parietal ring-enhancing lesion, which on resection was shown to be a necrotizing granuloma. There were no associated pulmonary lesions, and the patient was systemically well. Sputum and urine cultures were negative for tuberculosis. The patient was treated with anti-tuberculous medications and made an excellent recovery. We consider this to be the first documented case of tuberculosis involving the central nervous system occurring in the setting of adalimumab treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20419463     DOI: 10.1007/s10067-010-1466-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

1.  [Pulmonary tuberculosis with cerebellar lesion in a patient after anti-TNF-alpha (infliximab) treatment for rheumatoid arthritis].

Authors:  Mikio Ubukata; Noboru Takayanagi; Tsutomu Yanagisawa; Yousuke Miyahara; Motoko Kubota; Kenichirou Hara; Hiroo Saitoh; Daidou Tokunaga; Kazuki Kurashima; Yutaka Sugita
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2005-04

2.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

3.  Diagnostic utility of polymerase chain reaction and immunohistochemical techniques for the laboratory diagnosis of intracranial tuberculoma.

Authors:  M G Sumi; A Mathai; R Sheela; N S Radhakrishnan; V V Radhakrishnan; R Indhulekshmy; S Mundayoor
Journal:  Clin Neuropathol       Date:  2001 Jul-Aug       Impact factor: 1.368

4.  Disseminated tuberculosis complicating anti-TNF-alpha treatment.

Authors:  K Dimakou; D Papaioannides; P Latsi; S Katsimboula; P Korantzopoulos; D Orphanidou
Journal:  Int J Clin Pract       Date:  2004-11       Impact factor: 2.503

Review 5.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

6.  Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.

Authors:  Guy E Thwaites; Duc Bang Nguyen; Huy Dung Nguyen; Thi Quy Hoang; Thi Tuong Oanh Do; Thi Cam Thoa Nguyen; Quang Hien Nguyen; Tri Thuc Nguyen; Ngoc Hai Nguyen; Thi Ngoc Lan Nguyen; Ngoc Lan Nguyen; Hong Duc Nguyen; Ngoc Tuan Vu; Huu Hiep Cao; Thi Hong Chau Tran; Phuong Mai Pham; Thi Dung Nguyen; Kasia Stepniewska; Nicholas J White; Tinh Hien Tran; Jeremy J Farrar
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

7.  Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.

Authors:  Johan Askling; C Michael Fored; Lena Brandt; Eva Baecklund; Lennart Bertilsson; Lars Cöster; Pierre Geborek; Lennart T Jacobsson; Staffan Lindblad; Jörgen Lysholm; Solbritt Rantapää-Dahlqvist; Tore Saxne; Victoria Romanus; Lars Klareskog; Nils Feltelius
Journal:  Arthritis Rheum       Date:  2005-07

8.  Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab.

Authors:  Angela Raval; Gita Akhavan-Toyserkani; Allen Brinker; Mark Avigan
Journal:  Ann Intern Med       Date:  2007-11-20       Impact factor: 25.391

9.  Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Authors:  Daniel E Furst; Michael H Schiff; Roy M Fleischmann; Vibeke Strand; Charles A Birbara; Daniele Compagnone; Steven A Fischkoff; Elliot K Chartash
Journal:  J Rheumatol       Date:  2003-12       Impact factor: 4.666

Review 10.  Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.

Authors:  Alberto Alonso-Ruiz; Jose Ignacio Pijoan; Eukene Ansuategui; Arantxa Urkaregi; Marcelo Calabozo; Antonio Quintana
Journal:  BMC Musculoskelet Disord       Date:  2008-04-17       Impact factor: 2.362

View more
  7 in total

Review 1.  Beyond the joints: neurological involvement in rheumatoid arthritis.

Authors:  Cesar Ramos-Remus; Sergio Duran-Barragan; Jose Dionisio Castillo-Ortiz
Journal:  Clin Rheumatol       Date:  2011-09-20       Impact factor: 2.980

Review 2.  Cytokines and Chemokines in Mycobacterium tuberculosis Infection.

Authors:  Racquel Domingo-Gonzalez; Oliver Prince; Andrea Cooper; Shabaana A Khader
Journal:  Microbiol Spectr       Date:  2016-10

Review 3.  Central Nervous System Infections Associated with Immunosuppressive Therapy for Rheumatic Disease.

Authors:  Michael J Bradshaw; Tracey A Cho; Felicia C Chow
Journal:  Rheum Dis Clin North Am       Date:  2017-08-23       Impact factor: 2.670

4.  Suprasellar tuberculoma presenting as sudden onset blindness in a patient of lupus.

Authors:  Rudrajit Paul; Amit K Banerjee; Ramtanu Bandyopadhyay
Journal:  J Glob Infect Dis       Date:  2012-01

Review 5.  Microglia are crucial regulators of neuro-immunity during central nervous system tuberculosis.

Authors:  Jonathan Paul Spanos; Nai-Jen Hsu; Muazzam Jacobs
Journal:  Front Cell Neurosci       Date:  2015-05-18       Impact factor: 5.505

6.  TNF-dependent regulation and activation of innate immune cells are essential for host protection against cerebral tuberculosis.

Authors:  Ngiambudulu M Francisco; Nai-Jen Hsu; Roanne Keeton; Philippa Randall; Boipelo Sebesho; Nasiema Allie; Dhirendra Govender; Valerie Quesniaux; Bernhard Ryffel; Lauriston Kellaway; Muazzam Jacobs
Journal:  J Neuroinflammation       Date:  2015-06-26       Impact factor: 8.322

7.  Central nervous system infections in travelers.

Authors:  H L Kirsch; K T Thakur; G L Birbeck
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.663

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.